Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(2 Publications)
Human Recombinant Monoclonal SPIKE antibody. Carrier free. Suitable for I-ELISA and reacts with Recombinant full length protein - SARS-CoV-2 samples. Cited in 2 publications.
View Alternative Names
2, S, Spike glycoprotein, S glycoprotein, E2, Peplomer protein
- I-ELISA
Lab
Indirect ELISA - Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (AB277515)
This data was produced using the same clone but in a different formulation, ab277513.
Indirect competition ELISA showing competitive binding of ab277513 (CV30) to ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)) in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well ab272105 and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
- I-ELISA
Lab
Indirect ELISA - Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (AB277515)
This data was produced using the same clone but in a different formulation, ab277513.
Indirect competition ELISA showing competitive binding of ab277513 (CV30) to purified Fc-tagged SARS-CoV2-RBD in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well SARS-CoV2-RBD and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
- I-ELISA
Lab
Indirect ELISA - Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (AB277515)
This data was produced using the same clone but in a different formulation, ab277513.
Indirect ELISA showing ab277513 (CV30) binding to purified His-tagged SARS-CoV2-RBD. Plates were coated with 100ng/well purified protein and binding of ab277513 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
- I-ELISA
Lab
Indirect ELISA - Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (AB277515)
This data was produced using the same clone but in a different formulation, ab277513.
Indirect ELISA showing ab277513 (CV30) binding to ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)). Plates were coated with 100ng/well ab272105 and binding of ab277513 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
Related conjugates and formulations (1)
-
Anti-SARS-CoV-2 Spike RBD antibody [CV30]
Reactivity data
Product details
CV30 cross-reacts with both SARS-CoV-2 Spike RBD and Ectodomain. CV30 demonstrates significant neutralising ability in in-direct ELISA, measuring competitive binding of CV30 to SARS-CoV-2 Spike RBD in the presence of human ACE2.
ab277515 is the carrier-free version of ab277513.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
Properties and storage information
Form
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The SARS-CoV-2 Spike RBD interacts directly with the host ACE2 receptor to mediate entry of the virus into host cells. This interaction is necessary for the virus to fuse with the host cell membrane which allows viral RNA to enter the host cell and begin replication. The Spike protein of which the RBD is a part forms a trimeric complex on the virus surface that is important for host interaction. Variations in the Spike RBD such as mutations like Arg319-Phe541 have significant impacts on the binding affinity to ACE2 and the effectiveness of vaccine-elicited antibodies.
Pathways
The Spike RBD of SARS-CoV-2 is vital in the entry pathway of the virus into the host cell. It is prominently involved in the ACE2-mediated signaling pathway with ACE2 playing the key role as the cellular receptor. This pathway is integral to the pathogenesis of COVID-19. Additionally the presence of the virus in host cells can trigger inflammatory pathways via infection-induced signaling cascades which can lead to exacerbated immune responses.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (2)
Recent publications for all applications. Explore the full list and refine your search
Nature communications 11:5413 PubMed33110068
2020
Applications
Unspecified application
Species
Unspecified reactive species
Immunity 53:98-105.e5 PubMed32561270
2020
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com